Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Guidelines

Gå till Stäng Överst

DTG + RPV now recommended by DHHS and EACS in treatment guidelines1,2


DHHS Guidelines, October 2017

  • DTG + RPV receives AI recommendation* for switching suppressed patients1

*Strong recommendation based on 1 or more randomised trials with clinical outcomes and/or validated laboratory endpoints.1

>> View DHHS guidelines

 

EACS Guidelines, October 2017

  • DTG + RPV included as a switch strategy for virologically suppressed patients.2

>> View EACS guidelines

References:

  1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 17, 2017. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed February 12, 2018.
  2. European AIDS Clinical Society. Guidelines. Version 9.0. October 2017. http://www.eacsociety.org/files/guidelines_9.0-english.pdf. Accessed February 12, 2018.

JULUCA is owned by or licensed to the ViiV Healthcare group of companies.